Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

1.

Cortical abnormalities in episodic migraine: A multi-center 3T MRI study.

Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, Amin FM, Seifert CL, Mallar Chakravarty M, Müller J, Sprenger T.

Cephalalgia. 2018 Dec 10:333102418795163. doi: 10.1177/0333102418795163. [Epub ahead of print]

PMID:
30525946
2.

Design and construction of an innovative brain phantom prototype for MRI.

Altermatt A, Santini F, Deligianni X, Magon S, Sprenger T, Kappos L, Cattin P, Wuerfel J, Gaetano L.

Magn Reson Med. 2019 Feb;81(2):1165-1171. doi: 10.1002/mrm.27464. Epub 2018 Sep 17.

PMID:
30221790
3.

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.

Nakamura Y, Gaetano L, Matsushita T, Anna A, Sprenger T, Radue EW, Wuerfel J, Bauer L, Amann M, Shinoda K, Isobe N, Yamasaki R, Saida T, Kappos L, Kira JI.

J Neuroinflammation. 2018 Sep 5;15(1):255. doi: 10.1186/s12974-018-1295-1.

4.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2018 Aug 28. doi: 10.1007/s11682-018-9942-9. [Epub ahead of print]

PMID:
30155789
5.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.

Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6.

6.

Spinal cord volume loss: A marker of disease progression in multiple sclerosis.

Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, Stippich C, Cattin P, Wuerfel J, Bieri O, Sprenger T, Kappos L, Parmar K.

Neurology. 2018 Jul 24;91(4):e349-e358. doi: 10.1212/WNL.0000000000005853. Epub 2018 Jun 27.

PMID:
29950437
7.

Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR, Rödel C, Ghadimi M.

Br J Surg. 2018 Oct;105(11):1510-1518. doi: 10.1002/bjs.10877. Epub 2018 May 30.

PMID:
29846017
8.

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset.

Altermatt A, Gaetano L, Magon S, Häring DA, Tomic D, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Brain Topogr. 2018 Sep;31(5):886-894. doi: 10.1007/s10548-018-0652-9. Epub 2018 May 29.

PMID:
29845492
9.

Cortical Thickness Alterations in Chronic Pain Disorder: An Exploratory MRI Study.

Magon S, Sprenger T, Otti A, Papadopoulou A, Gündel H, Noll-Hussong M.

Psychosom Med. 2018 Sep;80(7):592-598. doi: 10.1097/PSY.0000000000000605.

PMID:
29787468
10.

Preferential spinal cord volume loss in primary progressive multiple sclerosis.

Tsagkas C, Magon S, Gaetano L, Pezold S, Naegelin Y, Amann M, Stippich C, Cattin P, Wuerfel J, Bieri O, Sprenger T, Kappos L, Parmar K.

Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006. [Epub ahead of print]

PMID:
29781383
11.

Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Sprenger T, Viana M, Tassorelli C.

Neurotherapeutics. 2018 Apr;15(2):313-323. doi: 10.1007/s13311-018-0621-8. Review.

PMID:
29671241
12.

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.

Gaetano L, Häring DA, Radue EW, Mueller-Lenke N, Thakur A, Tomic D, Kappos L, Sprenger T.

Neurology. 2018 Apr 10;90(15):e1324-e1332. doi: 10.1212/WNL.0000000000005292. Epub 2018 Mar 14.

PMID:
29540589
13.

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T; MAGNIMS study group.

Neurosci Biobehav Rev. 2018 Jun;89:85-98. doi: 10.1016/j.neubiorev.2018.02.012. Epub 2018 Feb 23. Review.

PMID:
29477616
14.

Superior Effects of High-Intensity Interval Training vs. Moderate Continuous Training on Arterial Stiffness in Episodic Migraine: A Randomized Controlled Trial.

Hanssen H, Minghetti A, Magon S, Rossmeissl A, Papadopoulou A, Klenk C, Schmidt-Trucksäss A, Faude O, Zahner L, Sprenger T, Donath L.

Front Physiol. 2017 Dec 19;8:1086. doi: 10.3389/fphys.2017.01086. eCollection 2017.

15.

Effects of different endurance exercise modalities on migraine days and cerebrovascular health in episodic migraineurs: A randomized controlled trial.

Hanssen H, Minghetti A, Magon S, Rossmeissl A, Rasenack M, Papadopoulou A, Klenk C, Faude O, Zahner L, Sprenger T, Donath L.

Scand J Med Sci Sports. 2018 Mar;28(3):1103-1112. doi: 10.1111/sms.13023. Epub 2018 Jan 8.

PMID:
29161767
16.

A 1-minute full brain MR exam using a multicontrast EPI sequence.

Skare S, Sprenger T, Norbeck O, Rydén H, Blomberg L, Avventi E, Engström M.

Magn Reson Med. 2018 Jun;79(6):3045-3054. doi: 10.1002/mrm.26974. Epub 2017 Oct 31.

PMID:
29090483
17.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15.

18.

Altered thalamic connectivity during spontaneous attacks of migraine without aura: A resting-state fMRI study.

Amin FM, Hougaard A, Magon S, Sprenger T, Wolfram F, Rostrup E, Ashina M.

Cephalalgia. 2018 Jun;38(7):1237-1244. doi: 10.1177/0333102417729113. Epub 2017 Aug 30.

PMID:
28853611
19.

Daclizumab for the treatment of multiple sclerosis.

Papadopoulou A, Derfuss T, Sprenger T.

Neurodegener Dis Manag. 2017 Oct;7(5):279-297. doi: 10.2217/nmt-2017-0023. Epub 2017 Aug 29. Review.

PMID:
28849702
20.

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.

Radue EW, Sprenger T, Gaetano L, Mueller-Lenke N, Cavalier S, Thangavelu K, Panzara MA, Donaldson JE, Woodward FM, Wuerfel J, Wolinsky JS, Kappos L.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 9;4(5):e390. doi: 10.1212/NXI.0000000000000390. eCollection 2017 Sep.

Supplemental Content

Loading ...
Support Center